Document is current

Article History

Received: 25 July 2024

Accepted: 5 January 2025

First Online: 21 January 2025

Declarations

:

: The retrospective data collection was approved by the Ethics Committee of the University of Heidelberg (protocol number: S-565/2011), which complied with the provisions of the Good Clinical Practice guidelines and the Declaration of Helsinki and local laws and fulfilled Regulation (EU) 2016/679 of the European Parliament and the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data (ID number DSAN854-A-OS/5).

: Written informed consent for the procedure and management was obtained from all individual participants included in the study.

: IM advises for Univar, received travel grants from Univar and received speaker fees from Orphalan. PL, CW, VYL, SK, AO, ML, AL, PD, MG, SW and HZ declare no conflicts of interest. PM received honoraria from Falk, Orphalan and AstraZeneca. AP has received research (institutional) grants from Orphalan, AddMedica and Alexion; consulting fees from Orphalan, Univar, Alexion and Vivet Therapeutics; and speaker fees from Alexion and Orphalan. KHW has received research (institutional) grants from Orphalan; consulting fees from Orphalan, Univar, Pfizer, Alexion and Vivet Therapeutics; speaker fees from Falk, AbbVie, Alexion, and Orphalan; travel assistance to meetings from Alexion and Univar; and advisory board payments from Ultragenyx. UM received honoraria for teaching from Falk and Univar and received travel grants from Gilead and Falk.